Bioanalytical method validation: concepts, expectations and challenges in small molecule and macromolecule--a report of PITTCON 2013 symposium.
The concepts, importance, and implications of bioanalytical method validation has been discussed and debated for a long time. The recent high profile issues related to bioanalytical method validation at both Cetero Houston and former MDS Canada has brought this topic back in the limelight. Hence, a symposium on bioanalytical method validation with the aim of revisiting the building blocks as well as discussing the challenges and implications on the bioanalysis of both small molecules and macromolecules was featured at the PITTCON 2013 Conference and Expo. This symposium was cosponsored by the American Chemical Society (ACS)-Division of Analytical Chemistry and Analysis and Pharmaceutical Quality (APQ) Section of the American Association of Pharmaceutical Scientists (AAPS) and featured leading speakers from the Food & Drug Administration (FDA), academia, and industry. In this symposium, the speakers shared several unique examples, and this session also provided a platform to discuss the need for continuous vigilance of the bioanalytical methods during drug discovery and development. The purpose of this article is to provide a concise report on the materials that were presented.
Office of Clinical Pharmacology, Center for Drug Evaluations and Research, United States Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA.
Edward D
ED
Bashaw
Binodh
B
DeSilva
Mark J
MJ
Rose
Yow-Ming C
YM
Wang
Chinmay
C
Shukla
D002623:Chemistry Techniques, Analytical; D007883:Legislation, Medical; D046911:Macromolecular Substances / Q000032:analysis*; D010601:Pharmacology, Clinical; D054852:Small Molecule Libraries
D046911:Macromolecular Substances; D054852:Small Molecule Libraries